---

Clinical Case: Mitral Stenosis

Diagnosis

• Gradual-onset dyspnea + orthopnoea + PND - classic features of left-sided heart failure from elevated left atrial pressure
• Young female (30 years) - rheumatic MS has a 3:1 female preponderance and presents in the 3rd-4th decade in developing countries
• Mid-diastolic murmur at the mitral area - the pathognomonic auscultatory finding of MS (low-pitched rumbling murmur, best heard at the apex with the bell in left lateral position, breath held in expiration)

---

Pathophysiology

Step 1 - Structural Valve Changes

Step 2 - Left Atrial Pressure Rise

• Left atrial dilatation (hypertrophy of atrial muscle + interstitial fibrosis)
• Atrial fibrillation (AF) - the most common complication, seen in ~40% of patients
• LA thrombus formation (especially in the left atrial appendage) - risk of systemic embolism

Step 3 - Pulmonary Venous Hypertension

• Pulmonary congestion and interstitial oedema - this produces dyspnoea on exertion, orthopnoea, and PND
• Haemoptysis (from rupture of dilated bronchial veins)
• Pulmonary oedema in severe cases

Step 4 - Pulmonary Arterial Hypertension (PAH)

1. Pulmonary arteriolar vasoconstriction (largely reversible after relief of MS)
2. Morphologic changes in the pulmonary vasculature - intimal thickening, medial hypertrophy (fixed component; may or may not reverse post-intervention)

Step 5 - Right Ventricular Failure

Summary Chain:

↓ MVA → ↑ LA pressure → LA dilatation + AF + thrombus → ↑ pulmonary venous pressure → pulmonary congestion (SOB, orthopnoea, PND) → ↑ PAP (reactive PAH) → RV pressure overload → RV hypertrophy → RV failure → ↓ cardiac output

---

Auscultatory Signs (Relevant to This Case)

---

Management

1. General Measures

• Activity restriction in symptomatic patients
• Salt restriction and weight management
• Antibiotic prophylaxis against Group A Streptococcus (penicillin monthly/daily) to prevent further rheumatic attacks - this is especially important for secondary prevention

2. Medical Therapy

3. Interventional Treatment - Relieving the Mechanical Obstruction

A. Percutaneous Balloon Mitral Valvotomy (PBMV / BMV)

• Procedure of choice for suitable anatomy
• A balloon catheter is advanced across the interatrial septum (transseptal puncture) and inflated across the mitral valve to split the fused commissures
• Indication: Symptomatic MS (NYHA class II-IV) with MVA ≤1.5 cm² AND favourable valve anatomy (Wilkins score ≤8)
• Contraindications: Significant MR (≥2+), LA thrombus, severe subvalvular disease, heavily calcified valves
• Results in immediate doubling of MVA, substantial reduction in transmitral gradient and LA pressure
• Long-term results: 5-year event-free survival of 60-90%

B. Surgical Options

• Open Mitral Commissurotomy (OMC) - surgical splitting of fused commissures on cardiopulmonary bypass; preferred when anatomy is borderline
• Mitral Valve Replacement (MVR) - for severely distorted, calcified valves or when significant MR coexists
  • Mechanical valve (St. Jude's bileaflet): requires lifelong anticoagulation; preferred in young patients
  • Bioprosthetic valve: no long-term anticoagulation needed; but limited durability (~15 years); preferred in elderly or those who cannot take anticoagulants

4. Management of Complications

---

Severity Assessment (ACC/AHA Classification)

---

Key Investigations to Order

1. Echocardiography (TTE) - mainstay of diagnosis; measures MVA (planimetry, pressure half-time), transmitral gradient, LA size, Wilkins score, pulmonary pressures, LV function
2. ECG - P-mitrale (bifid P in lead II, biphasic in V1), RVH, AF
3. Chest X-ray - straightening of left heart border (LA enlargement), double atrial shadow, Kerley B lines, pulmonary plethora
4. Cardiac catheterization - when echo inconclusive; measures transmitral gradient directly via simultaneous LA and LV pressures (or PCWP as surrogate)
5. TEE - rule out LA thrombus before PBMV or cardioversion

---

---

Clinical Case: 65-Year-Old Male with Acute Severe Retrosternal Chest Pain + Sweating x 3 Hours

Diagnosis: Acute ST-Elevation Myocardial Infarction (STEMI) - Until Proven Otherwise

---

Differential Diagnoses to Consider (and Exclude Rapidly)

---

STEP 1: IMMEDIATE APPROACH ON ARRIVAL (First 10 Minutes)

A. Simultaneous Assessment and Action - "TIME = MYOCARDIUM"

1. IV access - two large-bore peripheral lines
2. Monitoring - continuous cardiac monitor + pulse oximetry + blood pressure
3. 12-lead ECG - must be obtained and interpreted within 10 minutes of arrival (AHA/ACC guideline)
4. Brief targeted history - pain character, onset, duration, radiation, associated symptoms, risk factors, medications, contraindications to thrombolysis
5. Rapid physical examination - vitals (both arms BP to exclude aortic dissection), JVP, lung auscultation, heart sounds, peripheral pulses, neurological status

B. History to Obtain Rapidly

• Onset: Sudden? Activity-related?
• Provocation/Palliation: Nothing relieves it (unlike angina)
• Quality: Pressure, heaviness, tightness, crushing ("elephant sitting on chest")
• Radiation: Left arm, jaw, neck, epigastrium (inferior MI), back (dissection)
• Severity: Usually severe, 8-10/10
• Time: Duration ≥ 20 minutes suggests MI

• Prior intracranial haemorrhage, recent stroke within 3 months, major surgery within 3 weeks, active bleeding, SBP >180 mmHg, aortic dissection, acute pericarditis, pregnancy

---

STEP 2: IMMEDIATE INVESTIGATIONS

A. ECG (Most Critical - Do First)

• Men >40 years: ≥2 mm in V2-V3, ≥1 mm in all other leads
• Right-sided leads (V3R, V4R): must be obtained in inferior MI to rule out RV infarction (treated differently - avoid nitrates and diuretics)

1. Hyperacute peaked T waves (earliest sign, minutes)
2. ST elevation (within hours)
3. Q wave development (transmural necrosis, hours to days)
4. T wave inversion
5. ST normalisation

B. Blood Tests (Send Simultaneously - Do NOT Wait for Results Before Starting Treatment)

C. Chest X-Ray (Portable)

• Pulmonary oedema (Kerley B lines, perihilar haziness, cardiomegaly)
• Wide mediastinum (aortic dissection)
• Pneumothorax (alternative diagnosis)
• Cardiomegaly

D. Echocardiography (Bedside TTE)

• If diagnosis is unclear after ECG and history
• Identifies regional wall motion abnormalities confirming ischemia
• Assesses LV function (EF), RV function, pericardial effusion, mechanical complications (MR, VSD)

---

STEP 3: IMMEDIATE MANAGEMENT ("MONA-B" + Reperfusion)

Initial Stabilisation

• Oxygen - only if SpO₂ <90%; routine oxygen in normoxaemic patients is not beneficial and may be harmful
• IV access - two large-bore lines
• Continuous ECG monitoring - ready for defibrillation (VF causes 50% of early STEMI mortality, often in the first hour)
• Position - sitting position or semi-recumbent if breathless

A. Antiplatelet Therapy (Immediate, Dual Antiplatelet - DAPT)

B. Anticoagulation

C. Anti-ischaemic Therapy

D. Reperfusion Therapy - THE PRIORITY

Option 1: Primary PCI (Percutaneous Coronary Intervention) - PREFERRED

• Goal: Door-to-balloon time ≤90 minutes from first medical contact
• Superior to thrombolysis in all outcomes: better vessel patency (TIMI 3 flow), less re-infarction, less intracranial haemorrhage, improved survival
• Preferred in ALL of these situations:
  • PCI available within 90 min
  • Cardiogenic shock / Killip class III-IV (even if transfer required)
  • Contraindications to thrombolysis
  • Late presentation (>3h from symptom onset)
  • Prior CABG or PCI

Option 2: Fibrinolytic (Thrombolytic) Therapy

• When: Primary PCI not available within 120 minutes (transfer time >120 min)
• Goal: Door-to-needle time ≤30 minutes
• Most effective in first 3 hours of symptom onset; benefit tapers after 3h but still given up to 12h
• Transfer to PCI-capable centre after fibrinolysis for routine angiography within 24 hours

• Chest pain relief
• ≥50% reduction in ST elevation
• Idioventricular rhythm (accelerated idioventricular rhythm)
• Peak CK-MB at 12h (earlier than expected)

Absolute Contraindications to Thrombolysis:

• Prior intracranial haemorrhage
• Ischaemic stroke within 3 months
• Known intracranial structural lesion (AVM, aneurysm)
• Aortic dissection
• Active bleeding / bleeding diathesis
• Acute pericarditis
• Closed head injury within 3 months
• Severe uncontrolled hypertension (SBP >180 mmHg, DBP >110 mmHg)

---

STEP 4: SUBSEQUENT MANAGEMENT (In-Hospital)

E. Additional Medications

F. Monitoring and Complications to Watch For

Killip Classification (Risk Stratification)

---

STEP 5: SECONDARY PREVENTION (Before Discharge)

• DAPT for 12 months (aspirin lifelong)
• Beta-blocker (metoprolol/bisoprolol) - long-term
• High-intensity statin (atorvastatin 80 mg) - lifelong
• ACE inhibitor/ARB - especially if LVEF ≤40%
• Cardiac rehabilitation programme
• Risk factor modification: Smoking cessation, blood pressure control, diabetes management, weight loss, exercise
• Echocardiography before discharge to assess LV function

---

Summary Timeline (AHA/ACC Targets)

---

---

Lab Report Interpretation: High Sensitivity C-Reactive Protein (hs-CRP)

Patient Details

• Name: Debashree Mandal
• Age/Sex: 19 years / Female
• Sample: Serum (Barcode: 0F097971)
• Test Package: Aarogyam C Pro Package (Thyrocare)
• Method: Immunoturbidimetry (Fully Automated Latex Agglutination - Beckman Coulter)
• Report Date: 21 Jun 2026

---

Result at a Glance

---

What Does This Result Mean?

---

What is hs-CRP? Understanding the Test

• Acute infection or tissue injury (rises 100-1000x)
• Chronic low-grade systemic inflammation (small but measurable rise)

• <1 mg/L = Low cardiovascular risk
• 1-3 mg/L = Intermediate/Average cardiovascular risk
• >3 mg/L = High cardiovascular risk

---

How to Interpret This Result in Context: A 19-Year-Old Female

Is this concerning?

• Traditional 10-year cardiovascular risk is essentially very low regardless
• The hs-CRP here is more likely signalling underlying low-grade inflammation rather than established atherosclerotic disease

---

One Important Caveat: Single Test Limitation

"A coronary artery disease risk assessment should be based on the average of two hs-CRP tests, ideally taken two weeks apart."

• If hs-CRP >10 mg/L - discard the result; look for acute infection or inflammation, repeat in 2 weeks
• For the 1-3 mg/L range - a second measurement 2 weeks later is recommended to confirm the finding before drawing conclusions

---

Recommended Next Steps

Immediate

1. Repeat hs-CRP in 2 weeks (standard recommendation before drawing any clinical conclusion)
2. Correlate with clinical symptoms - any fever, fatigue, joint pains, skin rash, pelvic symptoms?

Investigations to Consider (with clinical correlation)

Lifestyle Interventions (Regardless of Cause)

• Regular aerobic exercise (30 min/day, 5 days/week) - reduces hs-CRP by ~30%
• Dietary modification - Mediterranean diet, reduce processed foods and refined carbohydrates
• Weight loss if overweight - even modest 5-10% reduction significantly lowers hs-CRP
• Smoking cessation if applicable
• Adequate sleep (chronic sleep deprivation raises CRP)
• Stress management

---

Summary

---

---

Lab Report Interpretation: hs-CRP (High Sensitivity C-Reactive Protein)

Patient Summary

---

Test Result

---

Reference Intervals (as per report)

---

Interpretation

1. Where Does 2.78 mg/L Fall?

• < 1 mg/L = Low cardiovascular risk
• 1-3 mg/L = Intermediate/Average risk
• > 3 mg/L = High cardiovascular risk
• The 2019 ACC/AHA Primary Prevention Guideline additionally designates hs-CRP ≥ 2.0 mg/L as an "ASCVD risk enhancer" - a finding that should prompt closer attention and possible therapeutic decisions.

---

2. Is This Expected for a 19-Year-Old Female?

---

3. What Could Cause This Elevation?

---

4. What Does This Mean for Cardiovascular Risk?

• Identify reversible causes of inflammation
• Motivate early lifestyle change
• Prevent long-term risk accumulation

---

5. The Single-Test Limitation

"A coronary artery disease risk assessment should be based on the average of two hs-CRP tests, ideally taken two weeks apart."

• A single result can be affected by transient factors (recent illness, physical exertion, menstrual phase)
• If hs-CRP > 10 mg/L: discard, look for acute cause, repeat in 2 weeks
• For values in the 1-3 mg/L range: confirm with a second test 2 weeks later before drawing conclusions

---

Recommended Action Plan

Step 1: Repeat the Test

• Repeat hs-CRP in 2 weeks under resting, non-infected conditions
• Avoid testing during menstruation, after exercise, or if unwell

Step 2: Additional Investigations (Correlate Clinically)

Step 3: Lifestyle Modifications (Evidence-Based - Lower hs-CRP)

---

Summary

---